CMPX•benzinga•April 1, 2025 at 11:07 AM

Compass Therapeutics Announced Statistically Significant Top-line Data On The Primary Efficacy Endpoint For COMPANION-002, The Company's Ongoing Phase 2/3 Trial Of Tovecimig (Formerly CTX-009) In Combination With Paclitaxel In Patients With Advanced Bilia

No summary available.

Read the full article from the original source for complete details and context.

Article published on April 1, 2025 by benzinga